Group One Trading’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11K | Sell |
9,200
-33,600
| -79% | -$40.9K | ﹤0.01% | 6323 |
|
|
2025
Q4 | $42.1K | Buy |
42,800
+20,100
| +89% | +$24.1K | ﹤0.01% | 5746 |
|
|
2025
Q3 | $28.6K | Sell |
22,700
-29,800
| -57% | -$32.1K | ﹤0.01% | 6413 |
|
|
2025
Q2 | $58.8K | Buy |
52,500
+37,500
| +250% | +$43.6K | ﹤0.01% | 5442 |
|
|
2025
Q1 | $11.9K | Buy |
15,000
+13,600
| +971% | +$16.7K | ﹤0.01% | 6146 |
|
|
2024
Q4 | $2.31K | Sell |
1,400
-12,300
| -90% | -$31K | ﹤0.01% | 6692 |
|
|
2024
Q3 | $48K | Sell |
13,700
-5,000
| -27% | -$19.5K | ﹤0.01% | 4682 |
|
|
2024
Q2 | $61.3K | Buy |
18,700
+14,000
| +298% | +$61.3K | ﹤0.01% | 4371 |
|
|
2024
Q1 | $34.5K | Buy |
4,700
+4,400
| +1,467% | +$27.2K | ﹤0.01% | 5014 |
|
|
2023
Q4 | $1.12K | Sell |
300
-400
| -57% | -$944 | ﹤0.01% | 6970 |
|
|
2023
Q3 | $1.48K | Sell |
700
-12,400
| -95% | -$41.1K | ﹤0.01% | 7130 |
|
|
2023
Q2 | $62.4K | Sell |
13,100
-1,900
| -13% | -$10.5K | ﹤0.01% | 5081 |
|
|
2023
Q1 | $85.5K | Buy |
15,000
+12,200
| +436% | +$73.6K | ﹤0.01% | 4434 |
|
|
2022
Q4 | $28.3K | Sell |
2,800
-3,800
| -58% | -$71.4K | ﹤0.01% | 5386 |
|
|
2022
Q3 | $148K | Sell |
6,600
-2,200
| -25% | -$63.6K | ﹤0.01% | 4422 |
|
|
2022
Q2 | $218K | Sell |
8,800
-12,300
| -58% | -$339K | ﹤0.01% | 4218 |
|
|
2022
Q1 | $818K | Sell |
21,100
-28,700
| -58% | -$1.11M | ﹤0.01% | 3291 |
|
|
2021
Q4 | $2.91M | Buy |
49,800
+38,000
| +322% | +$2.15M | ﹤0.01% | 2213 |
|
|
2021
Q3 | $699K | Buy |
11,800
+2,700
| +30% | +$212K | ﹤0.01% | 3816 |
|
|
2021
Q2 | $790K | Sell |
9,100
-22,000
| -71% | -$1.77M | ﹤0.01% | 3670 |
|
|
2021
Q1 | $2.56M | Buy |
31,100
+20,700
| +199% | +$1.98M | ﹤0.01% | 2187 |
|
|
2020
Q4 | $946K | Buy |
10,400
+9,200
| +767% | +$571K | ﹤0.01% | 2690 |
|
|
2020
Q3 | $48K | Sell |
1,200
-3,700
| -76% | -$129K | ﹤0.01% | 4668 |
|
|
2020
Q2 | $168K | Sell |
4,900
-5,100
| -51% | -$152K | ﹤0.01% | 3533 |
|
|
2020
Q1 | $222K | Sell |
10,000
-2,500
| -20% | -$63.2K | ﹤0.01% | 2665 |
|
|
2019
Q4 | $245K | Buy |
12,500
+1,600
| +15% | +$25.4K | ﹤0.01% | 3021 |
|
|
2019
Q3 | $169K | Buy |
10,900
+9,900
| +990% | +$190K | ﹤0.01% | 3204 |
|
|
2019
Q2 | $20K | Sell |
1,000
-4,700
| -82% | -$84.7K | ﹤0.01% | 4177 |
|
|
2019
Q1 | $100K | Sell |
5,700
-9,500
| -63% | -$150K | ﹤0.01% | 3174 |
|
|
2018
Q4 | $195K | Sell |
15,200
-16,500
| -52% | -$230K | ﹤0.01% | 2709 |
|
|
2018
Q3 | $516K | Sell |
31,700
-29,300
| -48% | -$346K | ﹤0.01% | 2253 |
|
|
2018
Q2 | $692K | Buy |
61,000
+28,500
| +88% | +$314K | 0.01% | 2036 |
|
|
2018
Q1 | $317K | Buy |
32,500
+24,900
| +328% | +$239K | ﹤0.01% | 2406 |
|
|
2017
Q4 | $46K | Buy |
+7,600
| New | +$33.9K | ﹤0.01% | 3768 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
Group One Trading's FATE Position: Q1 2026 in Review
Group One Trading increased its Fate Therapeutics (FATE) stake by 110% in Q1 2026, buying an estimated $5.93K and bringing the position to 9,305 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6317.
Group One Trading first reported a position in FATE in Q2 2018 and has held it in 22 quarters since. The position peaked at $585K in Q1 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- Group One Trading held 9,305 shares of Fate Therapeutics worth $11.2K as of Q1 2026.
- Group One Trading bought 4,874 Fate Therapeutics shares in Q1 2026, an estimated $5.93K.
- Fate Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6317 holding.
- Group One Trading first reported a position in Fate Therapeutics in Q2 2018 and has held it in 22 quarters since.
- Group One Trading's Fate Therapeutics position peaked at $585K in Q1 2020.
- 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.